Search

Search Constraints

You searched for: Author/Creator Helliwell, P.

Search Results

2. AB0774 TIME TO RESPONSE FOR CLINICAL AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH TOFACITINIB, ADALIMUMAB OR PLACEBO. (2nd June 2020)

3. AB0813 GUSELKUMAB-TREATED PATIENTS ACHIEVED CLINICALLY MEANINGFUL IMPROVEMENT IN SYSTEMIC SYMPTOMS AS MEASURED WITH PROMIS INSTRUMENT: RESULTS FROM PHASE-3 PSORIATIC ARTHRITIS TRIAL DISCOVER 1. (2nd June 2020)

4. AB0824 WHICH PARAMETERS ARE RELEVANT IN THE IDENTIFYING AXIAL INVOLVEMENT IN PSORIATIC ARTHRITIS? – RESULTS OF A SURVEY AMONG ASAS AND GRAPPA MEMBERS. (2nd June 2020)

5. AB0827 IMPACT OF BASELINE BODY MASS INDEX ON THE EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS. (2nd June 2020)

6. AB0839 RELIABILITY OF COMPOSITE MEASURES FOR THE ASSESSMENT OF PSORIATIC ARTHRITIS. (2nd June 2020)

8. FRI0339 LONG-TERM EFFICACY OF THE ORAL SELECTIVE JANUS KINASE 1 INHIBITOR FILGOTINIB IN PSORIATIC ARTHRITIS: WEEK 52 RESPONSE PATTERNS IN INDIVIDUAL PATIENTS FROM AN OPEN-LABEL EXTENSION (OLE) STUDY (EQUATOR2). (2nd June 2020)

9. FRI0343 EFFICACY AND SAFETY OF FILGOTINIB, A SELECTIVE JANUS KINASE 1 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: SUBGROUP ANALYSES FROM A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL (EQUATOR). (2nd June 2020)

10. FRI0344 THE LONG-TERM EFFECT OF TREATING PSORIATIC ARTHRITIS WITH THE JANUS KINASE 1-SELECTIVE INHIBITOR FILGOTINIB ON LIPID PROFILES: AN ANALYSIS OF THE EQUATOR AND EQUATOR2 TRIALS. (2nd June 2020)